%0 Journal Article
%T Hyperkalemia in Patients on Peritoneal Dialysis: Clinical Use Experience with New Potassium-Binders
%A Gennaro Argentino
%A Mario Iorio
%A Alessandra Antonia Mele
%A Andrea Camocardi
%A Enrica Emanuela Cascone
%A Maria Elena Liberti
%A Adelia Sagliocca
%A Andrea Pota
%A Luigi Russo
%A Maria Luisa Sirico
%A Germano Terzini
%A Michele Cavasso
%A Chiara Mennillo
%A Francesca Nettuno
%A Raffaele Genualdo
%A Giuseppe Surfaro
%A Lucia Di Micco
%J Open Journal of Nephrology
%P 324-333
%@ 2164-2869
%D 2024
%I Scientific Research Publishing
%R 10.4236/ojneph.2024.143030
%X <b>Background:</b> Patients with end-stage kidney disease (ESKD) on maintenance dialysis have a high risk of developing hyperkalemia. In addition to traditional approaches, a new option for the management of patients on dialysis includes the use of a potassium binder, sodium zirconium cyclosilicate (SZC). We evaluated the effect and safety of SZC in patients with chronic PD. <b>Objective:</b> To present a case series that illustrates the real-world use of new potassium-binders in hyperkalemic patients on peritoneal dialysis. <b>Methods:</b> This case series collected 9 patients on PD with baseline potassium values &gt; 5.5 mmol/l and who were treated with SZC 5 g once a day. Data were collected at baseline and at 1, 2, and 3 months after initiation of treatment. <b>Results: </b>The median age of patients was 64.5 years and the median duration of observation was 90 &#177; 5 days. It was observed that median serum potassium decreased (5.8 mmol/l at baseline with a range of 5.8 mmol/L - 6.8 mmol/L versus 4.5 in the third month with a range of 3.6 mmol/L - 5.3 mmol/L) after SZC treatment. Adverse events were observed in 2 (22.2%). The unique adverse event was constipation and presented in 2 patients (22.2%). Constipation was mild and transient during the observation period. No adverse events of special interest were reported. <b>Conclusion</b>: Normokalemia was established and maintained in this series of patients treated with SZC. No episodes of hyper- or hypo-kalemia were observed. SCZ had a good safety profile and was well tolerated over 3 months.
%K SZC
%K Sodium Zirconium Cyclosilicate
%K Hyperkalaemia
%K Peritoneal Dialysis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=135481